Iron Deficiency Linked to Poor Outcomes in Kidney Transplant Recipients
HCPLive
MARCH 19, 2024
Iron deficiency, independent of anemia, may be a potentially modifiable target to improve patient-reported outcomes after kidney transplantation.
Machine Perfusion Could Help Address Transplant Crisis for Pediatric Liver Diseases
HCPLive
NOVEMBER 9, 2024
New data from the UNOS database presented at NASPGHAN 2024 details characteristics and outcomes of pediatric liver transplant patients receiving machine perfused organs.
Transplant 
92
92 
Minjee Kim, MD: Understanding Sleep’s Impact on Post-Liver Transplant Outcomes
HCPLive
NOVEMBER 17, 2024
Kim explains how poor sleep is linked to negative impacts on mental health, physical health, and frailty after liver transplantation.
Transplant 59
59 
HCV+ Organs Offer Better Waitlist, Survival Outcomes for Transplantation
HCPLive
NOVEMBER 5, 2024
Direct-acting antiviral agents have enabled more availability for organ transplant.
Transplant 59
59 
Outcome of Cardiac Implantable Electronic Devices in Pediatric Heart Transplant Recipients
HeartRhythm
AUGUST 21, 2024
Among pediatric patients undergoing orthotopic heart transplantation (OHT), 1-12% are reported to need a permanent pacemaker (PPM).1 1 There are limited studies on the outcomes of PPM placement, and the role of implantable cardioverter-defibrillator (ICD) in pediatric OHT remains unclear.
A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models
Journal of Clinical Investigation - Cardiology
MARCH 1, 2024
Long-term organ transplant survival remains suboptimal, and life-long immunosuppression predisposes transplant recipients to an increased risk of infection, malignancy, and kidney toxicity. Promoting the regulatory arm of the immune system by expanding Tregs may allow immunosuppression minimization and improve long-term graft outcomes.
Transplant 133
133 
Prolonged Perfusion Preserves Donor Livers, Allows Flexible Transplantation Timeline
HCPLive
JANUARY 12, 2024
Liver transplantation after prolonged preservation with dual hypothermic oxygenated machine perfusion yielded similar outcomes to standard perfusion, showing no compromised donor liver quality and equal safety for recipients.
Transplant 99
99 
The impact of bleeding on outcomes following lung transplantation: a retrospective analysis using the universal definition of perioperative bleeding
Journal of Cardiothoracic Surgery
JULY 24, 2024
Lung transplantation (LT) represents a high-risk procedure for end-stage lung diseases. This study describes the outcomes of patients undergoing LT that require massive transfusions as defined by the universal.
Transplant 52
52 
Revolutionary Genomic Study Sheds Light on Immune Microenvironment in Transplanted Pediatric Hearts
DAIC
FEBRUARY 13, 2024
THE TEXAS HEART INSTITUTE 2024 milla1cf Tue, 02/13/2024 - 17:56 February 13, 2024 — Pediatric heart transplantation has long been hailed as a life-saving intervention for children suffering from end-stage heart failure. This helps us gain a comprehensive understanding of the immune response dynamics within transplanted hearts."
Transplant 111
111 
Heart transplantation for pediatric patients with malignant arrhythmias: Indications and Outcomes
HeartRhythm
OCTOBER 7, 2024
When intractable, heart transplant (HTX) can become the only viable treatment. Arrhythmias can lead to cardiac arrest (CA) and heart failure. This rare, high-risk cohort has not been reported as a distinct group.
Toxic epidermal necrolysis following heart transplantation may caused by cefoperazone sodium and sulbactam sodium
Journal of Cardiothoracic Surgery
SEPTEMBER 22, 2024
The outcome of heart transplantation is significantly affected by perioperative infections. Individualised immunosuppression strategies are essential to reduce the risk of such infections.
What happens to patients awaiting urgent transplantation for refractory electrical storm when they are not transplanted?
HeartRhythm
SEPTEMBER 17, 2024
Urgent heart transplantation (HTx) may be considered when all previous strategies fail (1), albeit with substantial post-operative mortality (1). Although HTx is considered as a bail-out strategy, no data exist regarding outcomes of refractory ES patients listed for urgent HTx but ultimately not transplanted during the acute phase.
Transplant 40
40 
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
DAIC
MAY 31, 2024
By the end of the study cardiologists performed 10% fewer biopsies in the first year post-transplant and 40% fewer in the second year post-transplant despite an increase in follow-up biopsy rates for dual positives. Hanna , CareDx President and CEO.
Heart Transplant 105
105 
Abstract 4146828: Downregulation of ADAR1 Attenuates Hypothermic Cardioprotection in Aged Donor Hearts During Transplantation
Circulation
NOVEMBER 11, 2024
Heart transplantation remains a vital treatment for end-stage heart failure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need. Aged donor hearts, despite their availability, exhibit increased primary graft dysfunction and decreased survival rates post-transplantation.
Transplant 40
40 
Right Ventricular Function on Cardiovascular Magnetic Resonance Imaging and Long-Term Outcomes in Stable Heart Transplant Recipients
Circulation: Cardiovascular Imaging
APRIL 2, 2024
BACKGROUND:In heart transplant recipients, right ventricular (RV) dysfunction may occur for a variety of reasons. Whether RV dysfunction in the stable phase after heart transplantation is associated with long-term adverse outcomes is unknown. years after heart transplantation were included. Over a median follow-up of 4.4
Abstract 4146920: Potential Effects of Preoperative Blood Transfusions on Cardiac Transplantation Patient’s Postoperative Condition
Circulation
NOVEMBER 11, 2024
Cox regression results showed that there is an increased risk of mortality in patients who did not receive transfusions before transplant (p<0.0001).Conclusion:While Cox regression results showed that there is an increased risk of mortality in patients who did not receive transfusions before transplant (p<0.0001).Conclusion:While
Transplant 40
40 
Genomic study sheds light on immune microenvironment in transplanted pediatric hearts
Medical Xpress - Cardiology
FEBRUARY 12, 2024
Pediatric heart transplantation has long been hailed as a life-saving intervention for children suffering from end-stage heart failure. While the procedure offers hope, the long-term outcomes for these young patients remain suboptimal due to allograft rejection and graft failure.
Transplant 56
56 
Determinants of survival following heart transplantation in adults with congenital heart disease
Journal of Cardiothoracic Surgery
FEBRUARY 9, 2024
We examine the factors associated with heart transplant outcomes in this challenging population with complex anatomy requiring redo-sur. Adult patients surviving with congenital heart disease (ACHD) is growing.
Standardized risk-stratified cardiac assessment and early posttransplant cardiovascular complications in kidney transplant recipients
Frontiers in Cardiovascular Medicine
JANUARY 23, 2024
Introduction Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in kidney transplant recipient (KTR). There is a dearth of standardized guidelines on optimal cardiovascular evaluation of transplant candidates. Posttransplant MACE has a negative effect on grafts and patient outcomes.
Transplant 64
64 Midterm outcomes of patients with native heart recovery after Impella 5+ for cardiogenic shock
European Journal of Heart Failure
DECEMBER 1, 2024
Summary of key study outcomes. Methods and results This single-centre retrospective study examined midterm (180 days) outcomes of patients with CS supported by Impella 5+ who achieved heart recovery. The objective of the study is to examine whether Impella 5.0/5.5 The average duration of Impella support was 10.5 ± 8 days.
Abstract 4146823: Trends and Outcomes in Heart Failure Admissions and Cardiogenic Shock Among Patients with Congenital Heart Disease
Circulation
NOVEMBER 11, 2024
Heart transplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Variations in cardiogenic shock, MCS usage, and cardiac transplants emphasize the need for adaptive clinical practices to optimize patient outcomes.
Hematopoietic Stem Cell Transplantation Improves Pediatric SCD Outcomes
HCPLive
APRIL 9, 2024
A systematic review and meta-analysis of HSCT in children with sickle cell disease demonstrated pooled survival rates exceeding 90%.
Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association
Circulation
MARCH 11, 2024
Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking.
Transplant 45
45 
Qazi Corner, Edition 7: ERCP Timing, GLP-1 RA Considerations, Seronegative Villous Atrophy
HCPLive
AUGUST 23, 2024
The third quarterly issue of 2024 reviews early versus late ERCP outcomes post-transplant, the impact of GLP-1RA use on endoscopic management, and the differential diagnosis of seronegative villous atrophy.
Transplant 105
105 
External Validation of Proposed American Heart Association Algorithm for Cardiovascular Screening Before Kidney Transplantation
Journal of the American Heart Association
DECEMBER 12, 2023
BackgroundScreening for cardiovascular disease is currently recommended before kidney transplantation. Outcomes were degree of coronary heart disease, revascularization rate following screening, major adverse cardiovascular events, and all‐cause death. 10.8]; and HR, 2.1 [95% 3.9]) and all‐cause death (HR, 12.0 [95% 95% [CI, 4.6–31.4];
Transplant 40
40 
Organ Donation After Euthanasia Can Safely Expand Kidney Donor Pool, Study Finds
HCPLive
SEPTEMBER 25, 2024
Leveraging deceased donor kidney transplantation data, study results suggest DCD-V kidney transplantation has similar short- and long-term outcomes versus DCD-III and DBD.
Transplant 64
64 
An explainable machine learning approach using contemporary UNOS data to identify patients who fail to bridge to heart transplantation
Frontiers in Cardiovascular Medicine
MAY 19, 2024
BackgroundThe use of Intra-aortic Balloon Pump (IABP) and Impella devices as a bridge to heart transplantation (HTx) has increased significantly in recent times. Out of them, 12% had primary outcomes indicating Status 2 failure. Our ML models were based on 19 variables from the UNOS data.
Feasibility Value of Right Ventricular Longitudinal Shortening Fraction and the Prognostic Implications in Patients With Heart Transplantation
Journal of the American Heart Association
MARCH 8, 2024
The value of RVLSF in the assessment of RV systolic function in recipients of heart transplantation (HT) and whether RVLSF can replace strain parameters remains unknown.Methods and ResultsA total of 153 adult patients who underwent HT were consecutively enrolled in this prospective longitudinal study.
Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study
DAIC
JANUARY 11, 2024
In organ transplantation, an extended criteria donor is defined as having perceived risk factors linked to poor subsequent outcomes, for example, those with age >55 or ischemic times exceeding 4 hours, which sometimes leads to rejection of the donor organ. utilizing the Paragonix SherpaPak CTS (p=0.022).
Transplant 111
111 
Abstract Sa1109: Aerobic Capacity of Adults with Fontan Palliation: Disease-specific Reference Values and Relationship to Outcomes
Circulation
NOVEMBER 11, 2024
We assessed the correlates of predicted peak VO2, and the relationship between predicted peak VO2quartiles and cardiovascular outcomes (death/transplant).Results:Of 1.28, p=0.02), and 4thquartile were associated with a higher risk of death/transplant (HR 1.32, 95% CI 1.16-1.69, 15.2 - 23.9) 1.69, p<0.001).Conclusions:The
Transplant 40
40 
Heart Failure Treatment Outcomes and Contraindications
HCPLive
MAY 21, 2024
Ashley Malliett, DMSc, MPAS, PA-C, discusses the importance of timely diagnosis and initiated care, as well as contraindications for transplants and LVAD.
In-Center Hemodialysis Patient Outcomes Negatively Impacted by Patient Care Technician Understaffing
HCPLive
MARCH 12, 2024
A greater patient-to-patient care technician ratio was associated with increased mortality and hospitalization with lower rates of waitlisting and transplantation among patients receiving in-center hemodialysis.
Patient Care 59
59 
Using stem cell-derived heart muscle cells to advance heart regenerative therapy
Science Daily - Heart Disease
APRIL 26, 2024
Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. The highly positive outcomes observed in primate models highlight the potential of this strategy. However, the risk of arrhythmias following this procedure is reportedly high.
Transplant 120
120 
Emergency Department Use and Hospital Mortality Among Heart Transplant Recipients in the United States
Journal of the American Heart Association
FEBRUARY 29, 2024
BackgroundAnnual heart transplant (HT) volumes have increased, as have post‐HT outpatient care needs. Multivariable logistic regression was used to predict outcomes of hospital admission and death. Journal of the American Heart Association, Ahead of Print. HT volumes and HT‐related ED visits increased from 2009 to 2018.
3-Year Left Ventricular Assist Device Outcomes and Strategy After Heart Transplant Allocation Score Change
The American Journal of Cardiology
JULY 6, 2024
Publication date: Available online 6 July 2024 Source: The American Journal of Cardiology Author(s): Jacob Agronin, Meredith Brown, Hannah Calvelli, Huaqing Zhao, Val Rakita, Yoshiya Toyoda, Mohammed Abul Kashem
Waitlist Outcomes in Candidates With Rare Causes of Heart Failure After Implementation of the 2018 French Heart Allocation Scheme
Circulation: Heart Failure
FEBRUARY 1, 2024
BACKGROUND:In 2018, an algorithm-based allocation system for heart transplantation (HT) was implemented in France. The cumulative incidence of waitlist mortality estimated with competing risk analysis and incidence of transplantation were compared between diagnosis groups. 4.24];P=0.03).CONCLUSIONS:Our
Abstract 4144326: Mid-Term Outcomes of Surgical Resection of Pediatric Cardiac Fibroma and Modified Ventricular Reconstruction Procedure
Circulation
NOVEMBER 11, 2024
It has changed the fate of young patients with large tumors who would have otherwise needed heart transplants, offering high suture strength and reducing postoperative complications. 2 steps were performed during modified ventricular reconstruction procedure. During a median follow-up period of 17.4
Pediatrics 40
40 
Stem cell-derived cardiomyocytes expressing a dominant negative pacemaker HCN4 channel do not reduce the risk of graft-related arrhythmias
Frontiers in Cardiovascular Medicine
JULY 8, 2024
BackgroundHuman pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) show tremendous promise for cardiac regeneration following myocardial infarction (MI), but their transplantation gives rise to transient ventricular tachycardia (VT) in large-animal MI models, representing a major hurdle to translation.
Pacemaker 52
52 
Ochsner Children’s Hospital Advocates to Close the Gap in Pediatric Heart Care
DAIC
FEBRUARY 21, 2024
As the only pediatric heart transplant program in Louisiana and the only program in the state to offer advanced mechanical support options for pediatric cardiology patients, Ochsner Children’s Hospital is committed to advocating for additional medical devices to enhance its high-quality care to pediatric patients awaiting transplant.
Pediatrics 105
105 RELIEVE-HF Trial Outcomes Reported at ACC.24 Find Impact of Interatrial Shunt May Vary by Heart Failure Type
DAIC
APRIL 6, 2024
Gregg Stone, MD “When you examine the outcomes in patients with heart failure across a broad range of left ventricular ejection fraction, the Ventura interatrial shunt was extremely safe but did not improve outcomes compared with no treatment. Researchers tracked outcomes in each participant for at least one year and up to two years.
RELIEVE-HF: Interatrial shunt in patients with heart failure
Cardiology Update
APRIL 25, 2024
The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Among patients with HFpEF, those who received the shunt experienced poor outcomes than those who did not.
Smidt Heart Institute Experts Selected to Join JACC Editorial Team
DAIC
JUNE 24, 2024
Kittleson, director of Heart Failure Research and director of Post Graduate Medical Education in Heart Failure and Transplantation, is an associate editor specializing in heart failure. She has been a section editor for Circulation: Cardiovascular Outcomes and Research, authored book chapters, and in 2022 was a finalist for the Samuel A.
Heart Failure 100
100 Abstract 4113494: Gut Microbiota Modulation by Immunosuppression and Cardiac Cell Therapy in a Nonhuman Primate Ischemia/Reperfusion Model of Cardiac Regeneration
Circulation
NOVEMBER 11, 2024
End-stage ischemic heart disease necessitates heart transplantation, and emerging cell therapy presents a promising solution to address donor scarcity. Disruption of gut microbiota significantly influences various diseases and treatments, including transplantation.
Ischemia 40
40 Abstract 4142247: Granzyme B PET Imaging for Non-Invasive Early Diagnosis of Acute Heart Allograft Rejection
Circulation
NOVEMBER 11, 2024
Background:Cardiac transplantation remains the single most effective treatment for end-stage heart failure. Despite the routine use of anti-rejection drugs in clinical practice, approximately 40% of cardiac transplant patients still experience unavoidable rejection. at POD 7 days; P<0.001).
Transplant 40
40 
Let's personalize your content